Efficacy of Somapacitan in Treatment-Fatigue Adult Patients With Growth Hormone Deficiency Previously Treated With Once-Daily Growth Hormone Injections: A 24-Week Randomized Active-Controlled Trial
Primary result · Change in Treatment Satisfaction Questionnaire for Medication-9 convenience scoreResult — go to the resultEstimated difference 23.2 points 95% CI 7.9–38.4Authors' conclusion
In AGHD patients who were fatigued from the long-term daily GH injections, somapacitan was reported to be more convenient than daily GH. It was effective in maintaining IGF-1 levels and body composition, glucose, lipids, and vascular parameters, comparable to daily GH. Nonsignificant decrease in BMD with somapacitan could reflect a favorable increase in bone metabolic units, as previously observed in naïve patients with GHD during the initial 6-month period of GH therapy.
Study context
- Population
- Adults with growth hormone deficiency (GHD) pretreated with daily growth hormone (GH) for ≥5 years who reported treatment-related fatigue
- Participants
- 29 adults
- Comparison
- Somapacitan vs daily GH
Methodological detailsactive-controlled
- Active-controlled
Primary result
As reported in the abstract
Estimated difference
23.2 points
95% CI 7.9–38.4
P = 0.004
Further findings
| Outcome | Estimated difference (gr/cm²) (95% CI) | P value | |
|---|---|---|---|
| BMD of the lumbar spine · baseline to study-end | −0.036 (−0.064 to −0.009) | P = 0.011 | |
| −0.1−0.0500.05Difference, gr/cm² (linear scale) |
IGF-1, glucose and lipid profile, visceral adipose tissue, fat mass (%), lean body mass, vascular parameters · baseline to study-end
- No differences between arms in estimated changes
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →